Toxicology International (Formerly Indian Journal of Toxicology)

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Overview on Alzheimer’s Disease


Affiliations
1 Department of Pharmacology, College of Pharmacy, Koneru Lakshmaiah Education Foundation, Vaddeswaram – 522502, Andhra Pradesh, India
     

   Subscribe/Renew Journal


The world wide spread dementia of Alzeheimer disease is estimated to be as high as 24 million and it is hypothesized to be double every 20 years through 2040 resulting to a costly risk of the disease. Alzehimer disease is the main cause of dementia and is manifested by a gradual loss of cognitive function which is initially begin with deterioration of memory. Before death, the patient is fully dependent on their care givers. The main mechanism underlying the neuropath logical changes in Alzheimer patient are remaining unknown. But mainly they may be affected by both environmental and genetic factors. The hall mark pathology of Alzheimer disease are mainly accompanied by the presence of reactive microgliosis and the loss of neurons, white matter and synapses3 .

Keywords

Dementia, Deterioration of Memory, Loss of Cognitive Function, Reactive Microgliosis, Synapses, White Matter
User
Subscription Login to verify subscription
Notifications
Font Size

  • Smith MA. Alzheimer disease. Int Rev Neurobiol. 1998; 42:1– 54. https://doi.org/10.1016/S0074-7742(08)60607-8.

  • Cummings JL, Cole G. Alzheimer disease. JAMA. 2002; 287(18):2335–8. https://doi.org/10.1001/jama.287.18.2335. PMid:11988038.

  • Braak H, Braak E. Neuropathological stageing of Alzheimerrelated changes. Acta Neuropathol. 1991; 82(4):239–59. https://doi.org/10.1007/BF00308809. PMid:1759558.

  • Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol. 2011; 7(3):137–52. https:// doi.org/10.1038/nrneurol.2011.2. PMid:21304480. PMCid:PMC3339565.

  • Cummings JL, Cole G. Alzheimer disease. JAMA. 2002; 287(18):2335–8. https://doi.org/10.1001/jama.287.18.2335. PMid:11988038.

  • Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012; 148(6):1204–22. https:// doi.org/10.1016/j.cell.2012.02.040. PMid:22424230. PMCid:PMC3319071.

  • Winslow BT, Onysko M, Stob CM, Hazlewood KA. Treatment of Alzheimer disease. Am Fam Physician. 2011; 83(12):1403–12.

  • Batsch NL, Mittelman MS. World Alzheimer Report 2012. Overcoming the Stigma of Dementia. Alzheimer’s Disease INTERNATIONAL (ADI), London; 2012.

  • Jonsson T, et al. Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med. 2013; 368(2):107–16.

  • Knuesel I, et al. Maternal immune activation and abnormal brain development across CNS disorders. Nat Rev Neurol. 2014; 10(11):643. https://doi.org/10.1038/nrneurol.2014.187. PMid:25311587.

  • Krstic D, Knuesel, I. Deciphering the mechanism underlying late-onset Alzheimer disease. Nat Rev Neurol. 2013; 9(1):25. https://doi.org/10.1038/nrneurol.2012.236. PMid:23183882.

  • Sosa-Ortiz, AL, Acosta-Castillo I, Prince MJ. Epidemiology of dementias and Alzheimer’s disease. Arch Med Res. 2012; 43(8):600–8. https://doi.org/10.1016/j.arcmed.2012.11.003. PMid:23159715.

  • Bonda DJ, et al. Role of metal dyshomeostasis in Alzheimer’s disease. Metallomics. 2011; 3(3): 267–70. https://doi.org/10.1039/c0mt00074d. PMid:21298161. PMCid:PMC3117398.

  • Van Gorp B, Vercruysse T. Frames and counter-frames giving meaning to dementia: A framing analysis of media content. Soc Sci Med. 2012; 74(8):1274–81. https://doi. org/10.1016/j.socscimed.2011.12.045. PMid:22386639.

  • Melo A, et al. Oxidative stress in neurodegenerative diseases: mechanisms and therapeutic perspectives. Oxid Med Cell Longev. 2011. https://doi.org/10.1155/2011/467180. PMid:22191013. PMCid:PMC3236428.

  • Christen Y. Oxidative stress and Alzheimer disease. Am J Clin Nutr. 2000; 71(2):621S–9S. https://doi.org/10.1093/ ajcn/71.2.621s. PMid:10681270.

  • Esler WP, Wolfe MS. A portrait of Alzheimer secretases--new features and familiar faces. Science. 2001; 293(5534):1449–54. https://doi.org/10.1126/science.1064638. PMid:11520976.

  • Skoog I, Kalaria RN, Breteler MM. Vascular factors and Alzheimer disease. Alzheimer Dis Assoc Disord. 1999; 13:S106–14. https://doi.org/10.1097/00002093-199912003- 00016. PMid:10609689.

  • Larson EB, et al. Survival after initial diagnosis of Alzheimer disease. Annals of internal medicine. 2004; 140(7):501–9. https://doi.org/10.7326/0003-4819-140-7- 200404060-00008. PMid:15068977.

  • Engelhart MJ, et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA. 2002; 287(24):3223–29. https:// doi.org/10.1001/jama.287.24.3223. PMid:12076218.

  • De la Torre JC. Alzheimer disease as a vascular disorder: Nosological Evidence. Stroke. 2002; 33(4):1152–62. https://doi.org/10.1161/01.STR.0000014421.15948.67. PMid:11935076.

  • Kozauer N, Katz R. Regulatory innovation and drug development for early-stage Alzheimer’s disease. N Engl J Med. 2013; 368(13):1169–71. https://doi.org/10.1056/ NEJMp1302513. PMid:23484795.

  • Rafii MS, Aisen PS. Recent developments in Alzheimer’s disease therapeutics. BMC Medicine. 2009; 7(1):1–4. https://doi.org/10.1186/1741-7015-7-7. PMid:19228370. PMCid:PMC2649159.

  • Crismon ML. Tacrine: first drug approved for Alzheimer’s disease. Ann Pharmacother. 1994; 28(6):744–51. https:// doi.org/10.1177/106002809402800612. PMid:7919566.

  • Mayeux R, Sano M. Treatment of Alzheimer’s disease. N Engl J Med. 1999; 341(22):1670–79. https://doi.org/10.1056/ NEJM199911253412207. PMid:10572156.

  • Molinuevo J L, et al. Current state of Alzheimer’s fluid biomarkers. Acta Neuropathol. 2018; 136(6):821–53. https:// doi.org/10.1007/s00401-018-1932-x. PMid:30488277. PMCid:PMC6280827.

  • Behrens S, et al. Use of FDA approved medications for Alzheimer’s disease in mild dementia is associated with reduced informal costs of care. Int Psychogeriatr. 2018; 30(10):1499. https://doi.org/10.1017/S104161021800011X. PMid:29559029. PMCid:PMC6150839.

  • Bassil N, Thaipisuttikul P, Grossberg GT. Memantine ER, a once-daily formulation for the treatment of Alzheimer’s disease. Expert Opin Pharmacother. 2010; 11(10):1765– 71. https://doi.org/10.1517/14656566.2010.493874. PMid:20540654.

  • Lleo A, Greenberg SM, Growdon JH. Current pharmacotherapy for Alzheimer’s disease. Annu Rev Med. 2006; 57:513–33. https://doi.org/10.1146/annurev. med.57.121304.131442. PMid:16409164.

  • Romero K, et al. The future is now: model‐based clinical trial design for Alzheimer’s disease. Clin Pharmacol Ther. 2015; 97(3):210–14. https://doi.org/10.1002/cpt.16. PMid:25669145. PMCid:PMC6463482.


Abstract Views: 107

PDF Views: 0




  • Overview on Alzheimer’s Disease

Abstract Views: 107  |  PDF Views: 0

Authors

Marshet Getachew Argaw
Department of Pharmacology, College of Pharmacy, Koneru Lakshmaiah Education Foundation, Vaddeswaram – 522502, Andhra Pradesh, India
Nagaraju Bandaru
Department of Pharmacology, College of Pharmacy, Koneru Lakshmaiah Education Foundation, Vaddeswaram – 522502, Andhra Pradesh, India

Abstract


The world wide spread dementia of Alzeheimer disease is estimated to be as high as 24 million and it is hypothesized to be double every 20 years through 2040 resulting to a costly risk of the disease. Alzehimer disease is the main cause of dementia and is manifested by a gradual loss of cognitive function which is initially begin with deterioration of memory. Before death, the patient is fully dependent on their care givers. The main mechanism underlying the neuropath logical changes in Alzheimer patient are remaining unknown. But mainly they may be affected by both environmental and genetic factors. The hall mark pathology of Alzheimer disease are mainly accompanied by the presence of reactive microgliosis and the loss of neurons, white matter and synapses3 .

Keywords


Dementia, Deterioration of Memory, Loss of Cognitive Function, Reactive Microgliosis, Synapses, White Matter

References